SNM applauds FDA's issuing of new drug manufacturing requirements

December 14, 2009

Reston, Va.--The U.S. Food and Drug Administration (FDA) announced publication of a final regulation on current good manufacturing practices (cGMPs) for the production of positron emission tomography (PET) drugs, as well as a guidance document describing acceptable approaches that would enable PET drug producers to meet the requirements in the proposed regulation.

"We are pleased that FDA has issued cGMPs for PET drugs, which are so important to the diagnosis and treatment of patients with heart disease, cancer and other life-threatening illnesses," said Michael M. Graham, PhD, MD, president of SNM and director of nuclear medicine at the University of Iowa Carver College of Medicine.

The new FDA guidelines, which will take effect December 11, 2011, are aimed at ensuring that PET drugs meet all requirements of safety, identity, strength, quality and purity. The cGMP guidance document describes acceptable approaches that would enable PET drug producers to meet regulatory requirements. All PET drug manufacturers will be required to submit a new drug application (NDA) or abbreviated new drug application (aNDA) for all PET drug products in routine clinical use by the date of implementation. In the interim, U.S. facilities must continue to comply with U.S. Phamacopeia <823>, which sets standards for the production of PET drugs.

SNM worked in concert with other medical organizations to provide FDA input and review on the cGMP guidelines. "This is a major step forward," said Graham. "Having a well-defined structure in place benefits manufacturers, physicians and patients by ensuring the highest quality drugs possible."

Through its Clinical Trials Network, SNM will offer educational programs on the new regulation. Representatives from FDA will discuss the new guidelines with the molecular imaging and manufacturing community at two upcoming events. FDA representatives will present a special session during the Clinical Trials Network Workshop, which will be held Feb. 1𔃀, 2010, at SNM's Conjoint Mid-Winter Meetings in Albuquerque, N.M. In addition, FDA representatives will present a half-day workshop at SNM's Annual Meeting, June 5𔃇, 2010, in Salt Lake City, Utah. To date, more than 130 manufacturing sites have registered with the Clinical Trials Network.
-end-
FDA's call announcing the new cGMP guidelines is available for replay through December 16. To access the recorded call, dial 800-756-0537. More information about the Clinical Trials Network and upcoming educational workshops is available at http://www.snm.org/clinicaltrials.

About SNM--Advancing Molecular Imaging and Therapy

SNM is an international scientific and medical organization dedicated to raising public awareness about what molecular imaging is and how it can help provide patients with the best health care possible. SNM members specialize in molecular imaging, a vital element of today's medical practice that adds an additional dimension to diagnosis, changing the way common and devastating diseases are understood and treated.

SNM's more than 17,000 members set the standard for molecular imaging and nuclear medicine practice by creating guidelines, sharing information through journals and meetings and leading advocacy on key issues that affect molecular imaging and therapy research and practice. For more information, visit http://www.snm.org.

Society of Nuclear Medicine

Related Positron Emission Tomography Articles from Brightsurf:

Single photon emission from isolated monolayer islands of InGaN
Single photon emitters are essential devices for the realization of future optical quantum technologies including optical quantum computing and quantum key distribution.

Corona-induced CO2 emission reductions are not yet detectable in the atmosphere
The impact of the corona pandemic will reduce worldwide carbon dioxide emissions by up to eight percent in 2020.

Dynamic full-field optical coherence tomography: 3D live-imaging of retinal organoids
Optical coherence tomography offers astounding opportunities to image the complex structure of living tissue but lacks functional information.

Measuring electron emission from irradiated biomolecules
Through a study published in EPJ D, researchers have successfully determined the characteristics of electron emission when high-velocity ions collide with adenine - one of the four key nucleobases of DNA.

Nondestructive positron beams probe damage, support safety advances in radiation environments
A multi-institution team has used positron beams to probe the nature of radiation effects, providing new insight into how damage is produced in iron films.

Plant roots increase carbon emission from permafrost soils
A key uncertainty in climate projections is the amount of carbon emitted by thawing permafrost in the Arctic.

Cryo-electron tomography reveals uromodulin's role in urinary tract infection protection
Free-flowing filaments of Uromodulin protect against urinary tract infections (UTIs) by duping potentially harmful bacteria to attach to their fishbone-like molecular architecture - rather than to sensitive urinary tract tissues - before being flushed out of the body during urination, researchers report.

Tomography studies of coins shed light on the history of Volga Bulgaria
Kazan Federal University, Joint Institute for Nuclear Research (Dubna, Russia), and Khalikov Institute of Archeology (Tatarstan Academy of Sciences, Kazan, Russia) are working together to study the physical properties of the coins found on the territory of former Volga Bulgaria.

Carbon emission from permafrost soils underestimated by 14%
Picture 500 million cars stacked in rows. That's how much carbon -- about 1,000 petagrams, or one billion metric tons - -is locked away in Arctic permafrost.

Carbon emission scheme 'succeeding despite low prices'
A European Union (EU) programme aimed at reducing carbon dioxide (CO2) emissions has made significant progress despite low prices in carbon markets, according to a study at the Universities of Strathclyde and Pittsburgh.

Read More: Positron Emission Tomography News and Positron Emission Tomography Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.